April 13, 2021
Seattle-based biotech AltPep, which spun out of bioengineering professor Valerie Daggett’s research lab in March 2019, has developed a platform that allows for both early diagnosis and treatment of Alzheimer’s. In January it raised $23 million in Series A investment funding to advance its work. AltPep’s tools identify diseases resulting from toxic misfolded amyloid proteins.